만성폐쇄성폐질환 : 시장 인사이트, 역학 및 예측(2024-2032년)

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease characterized by persistent respiratory symptoms and airflow limitation, primarily due to significant exposure to noxious particles or gases. It encompasses conditions like emphysema and chronic bronchitis, where inflammation and structural changes in the airways lead to narrowed air passages and reduced airflow. COPD is a major cause of morbidity and mortality globally, affecting over 65 million people and causing approximately 3 million deaths annually.

The Chronic Obstructive Pulmonary Disease Market is expected to grow around ~5% during the forecast period (2024-2032). The increasing number of regulatory approvals for new treatments and therapies is a significant driver in the COPD market. These approvals reflect advancements in medical research and a better understanding of the disease, which lead to the development of more effective and targeted therapies. The accelerated approval process by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) allows patients to access innovative treatments more quickly, improving disease management and patient outcomes. For instance, in February 2021, Europe Medicines Agency approved Trixeo Aerosphere (formoterol fumarate/glycopyrronium/budesonide) for the maintenance treatment of COPD. This triple therapy combines a LABA, a LAMA, and an inhaled corticosteroid (ICS).

Based on the marketed therapies, the market has been divided into Symbicort, Dupixent, Dalirespt, and others. Symbicort segment held a significant market share in 2023. Symbicort, a combination inhaler containing budesonide and formoterol, plays a significant role in the management of Chronic Obstructive Pulmonary Disease (COPD). Budesonide, a corticosteroid, reduces inflammation in the airways, while formoterol, a long-acting beta-agonist (LABA), helps relax the muscles around the airways to improve breathing. This dual-action mechanism makes Symbicort effective in both controlling symptoms and reducing the frequency of COPD exacerbations.

For a better understanding of the market adoption of Chronic Obstructive Pulmonary Disease, the market is analyzed based on its 7MM presence in countries such as The United States, Germany, UK, France, Italy, Spain, Japan. The United States held a dominant share of the market in 2023. The U.S. market for Chronic Obstructive Pulmonary Disease (COPD) is substantial, driven by the high prevalence and significant healthcare burden of the disease. According to the Centers for Disease Control and Prevention (CDC), approximately 16 million Americans are diagnosed with COPD, and millions more are likely undiagnosed. COPD is a leading cause of disability, reducing the quality of life for those affected and imposing a significant economic burden due to healthcare costs and lost productivity. The CDC reports that COPD costs the nation approximately $49.9 billion annually in healthcare expenditures and lost productivity.

Some of the major players operating in the market include AstraZeneca; GSK plc; Boehringer Ingelheim International GmbH; Sanofi; Regeneron Pharmaceuticals Inc.; Inmunotek; Novartis AG; Pulmotect, Inc; Amgen Inc.; and Verona Pharma plc.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Chronic Obstructive Pulmonary Disease Market
• 2.2. Research Methodology of the Chronic Obstructive Pulmonary Disease Market
• 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

• 3.1. Industry Synopsis
• 3.2. Segmental Outlook
  • 3.2.1. Market Growth Intensity
• 3.3. Regional Outlook

4.MARKET DYNAMICS

• 4.1. Drivers
• 4.2. Opportunity
• 4.3. Restraints
• 4.4. Trends

5.DISEASE BACKGROUND AND OVERVIEW

• 5.1. Introduction
• 5.2. Types of COPD
• 5.3. Causes
• 5.4. Risk Factors
• 5.5. Genetic Inheritance
• 5.6. Pathogenesis
• 5.7. Prognosis
• 5.8. Signs and Symptoms
• 5.9. Diagnosis
  • 5.9.1. Diagnosis Criteria
  • 5.9.2. Differential Diagnosis

6.TREATMENT

• 6.1. First Line Treatment - Bronchodilators
  • 6.1.1. Long-Acting Beta Agonists (LABAs)
  • 6.1.2. Short-Acting Muscarinic Antagonists (SAMAs)
  • 6.1.3. Long-Acting Muscarinic Antagonists (LAMAs)
• 6.2. Combination Inhalers
  • 6.2.1. LABA + LAMA
  • 6.2.2. LABA + Inhaled Corticosteroids (ICS)
  • 6.2.3. Triple Therapy (LABA + LAMA + ICS)
• 6.3. Inhaled Corticosteroids
• 6.4. Phosphodiesterase-4 Inhibitors
• 6.5. Mucolytics and Antioxidants
• 6.6. Antibiotics
• 6.7. Oxygen Therapy
• 6.8. Surgical and Interventional Therapies
  • 6.8.1. Lung Volume Reduction Surgery (LVRS)
  • 6.8.2. Bronchoscopic Lung Volume Reduction (BLVR)
  • 6.8.3. Lung Transplant
• 6.9. Emerging Therapies
  • 6.9.1. Biologic Therapy
  • 6.9.2. Gene Therapy
  • 6.9.3. Microbiome-Based Therapies
  • 6.9.4. Vaccines

7.PATIENT JOURNEY

8.EPIDEMIOLOGY & PATIENT POPULATION, 2022-2032F

• 8.1. Assumptions and Rationale
• 8.2. Epidemiology of Chronic Obstructive Pulmonary Disease in 7MM
  • 8.2.1. Total Prevalent Population of Chronic Obstructive Pulmonary Disease in the 7MM
  • 8.2.2. Age-specific Prevalent Population of Chronic Obstructive Pulmonary Disease in the 7MM
  • 8.2.3. Gender-specific Prevalent Population of Chronic Obstructive Pulmonary Disease in the 7MM

9.EPIDEMIOLOGY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY COUNTRY

• 9.1. The United States
  • 9.1.1. Total Prevalent Population of Chronic Obstructive Pulmonary Disease in the United States
  • 9.1.2. Age-specific Prevalent Population of Chronic Obstructive Pulmonary Disease in the United States
  • 9.1.3. Gender-specific Prevalent Population of Chronic Obstructive Pulmonary Disease in the United States
• 9.2. Germany
• 9.3. UK
• 9.4. France
• 9.5. Italy
• 9.6. Spain
• 9.7. Japan

10.CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET INSIGHTS, MARKETED THERAPIES

• 10.1. Symbicort (Budesonide and Formoterol): AstraZeneca
  • 10.1.1. Drug Profile
  • 10.1.2. Regulatory Achievements
  • 10.1.3. Other Development Activities
  • 10.1.4. Clinical Development
  • 10.1.5. Safety and Efficacy
• 10.2. Dupixent (Dupilumab): Regeneron Pharmaceuticals/Sanofi
• 10.3. Daliresp (Roflumilast): Allergan plc

11.CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET INSIGHTS, EMERGING THERAPIES

• 11.1. Itepekimab (SAR440340/REGN3500/Anti-IL-33 mAb): Sanofi/Regeneron Pharmaceuticals
  • 11.1.1. Drug Profile
  • 11.1.2. Clinical Development
  • 11.1.3. Safety and Efficacy
• 11.2. Fasenra (Benralizumab): AstraZeneca
• 11.3. Ensifentrine: Verona Pharma plc

12.CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET: 7MM ANALYSIS

• 12.1. Key Findings
• 12.2. Total Market Size of Chronic Obstructive Pulmonary Disease in the 7MM, 2022-2032F
• 12.3. Market Size of Chronic Obstructive Pulmonary Disease by Marketed Therapies in the 7MM
• 12.4. Market Size of Chronic Obstructive Pulmonary Disease by Emerging Therapies in the 7MM
• 12.5. United States Market Size, 2022-2032F
  • 12.5.1. Total Market Size of Chronic Obstructive Pulmonary Disease in the United States
  • 12.5.2. Market Size of Chronic Obstructive Pulmonary Disease by Marketed Therapies in the United States
  • 12.5.3. Market Size of Chronic Obstructive Pulmonary Disease by Emerging Therapies in the United States
• 12.6. Germany
• 12.7. UK
• 12.8. France
• 12.9. Italy
• 12.10. Spain
• 12.11. Japan

13.UNMET NEEDS

14.COMPETITIVE LANDSCAPE

• 14.1. Key Competitors - Marketed Therapies
• 14.2. Key Competitors - Phase III Drugs
• 14.3. Key Competitors - Phase II Drugs

15.COMPANY PROFILES

• 15.1. AstraZeneca
  • 15.1.1. Company Overview
  • 15.1.2. Key Financials
  • 15.1.3. SWOT Analysis
  • 15.1.4. Product Portfolio
  • 15.1.5. Recent Developments
• 15.2. GSK plc
• 15.3. Boehringer Ingelheim International GmbH
• 15.4. Sanofi
• 15.5. Regeneron Pharmaceuticals Inc.
• 15.6. Inmunotek
• 15.7. Novartis AG
• 15.8. Pulmotect, Inc.
• 15.9. Amgen Inc.
• 15.10. Verona Pharma plc

16.ACRONYMS & ASSUMPTION

17.ANNEXURE